Enhancement of radiosensitivity in human glioblastoma cells by the DNA N-mustard alkylating agent BO-1051 through augmented and sustained DNA damage response

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Chu, Pei Ming ^a   Chiou, Shih Hwa ^b,c   Su, Tsann Long ^d   Lee, Yi Jang ^c   Chen, Li Hsin ^c   Chen, Yi Wei ^b,c   Yen, Sang Hue ^b   Chen, Ming Teh ^b   Chen, Ming Hsiung ^b   Shih, Yang Hsin ^b   Tu, Pang Hsien ^d   Ma, Hsin I ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [BIS(2 CHLOROETHYL)AMINO]PHENYL] 3 [2 METHYL 5 (4 METHYLACRIDIN 9 YLAMINO)PHENYL]UREA; ALKYLATING AGENT; BO 1051; UNCLASSIFIED DRUG; BO-1051; CHLORMETHINE DERIVATIVE; DNA; RADIOSENSITIZING AGENT;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; CELLULAR DISTRIBUTION; DNA DAMAGE; DNA REPAIR; DRUG EFFECT; DRUG INHIBITION; DRUG STRUCTURE; GLIOBLASTOMA; HUMAN; HUMAN CELL; RADIOSENSITIVITY; ANIMAL; BIOLOGICAL MODEL; BRAIN TUMOR; DOSE RESPONSE; DRUG SCREENING; FEMALE; GENETICS; MOUSE; NUDE MOUSE; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; TUMOR CELL LINE; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CELL LINE, TUMOR; DNA DAMAGE; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLIOBLASTOMA; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NITROGEN MUSTARD COMPOUNDS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651500429     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-6-7     Document Type: Article

References (53)

1. Walker MD, Green SB, Byar DP, Alexander E, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey J, et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 303(23):1323-1329. 10.1056/NEJM198012043032303, 7001230.
2. Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002, 20(5):1375-1382. 10.1200/JCO.20.5.1375, 11870182.
3. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352(10):987-996. 10.1056/NEJMoa043330, 15758009.
4. Wadhwa PD, Zielske SP, Roth JC, Ballas CB, Bowman JE, Gerson SL. Cancer gene therapy: scientific basis. Annu Rev Med 2002, 53:437-452. 10.1146/annurev.med.53.082901.104039, 11818484.
5. Grando SA, Kawashima K, Wessler I. Introduction: the non-neuronal cholinergic system in humans. Life Sci 2003, 72(18-19):2009-2012. 10.1016/S0024-3205(03)00063-8, 12628450.
6. Maze R, Carney JP, Kelley MR, Glassner BJ, Williams DA, Samson L. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci USA 1996, 93(1):206-210. 10.1073/pnas.93.1.206, 40207, 8552605.
7. Gravatt GL, Baguley BC, Wilson WR, Denny WA. DNA-directed alkylating agents. 6. Synthesis and antitumor activity of DNA minor groove-targeted aniline mustard analogues of pibenzimol (Hoechst 33258). J Med Chem 1994, 37(25):4338-4345. 10.1021/jm00051a010, 7527862.
8. Gourdie TA, Valu KK, Gravatt GL, Boritzki TJ, Baguley BC, Wakelin LP, Wilson WR, Woodgate PD, Denny WA. DNA-directed alkylating agents. 1. Structure-activity relationships for acridine-linked aniline mustards: consequences of varying the reactivity of the mustard. J Med Chem 1990, 33(4):1177-1186. 10.1021/jm00166a015, 2319563.
9. Bacherikov VA, Chou TC, Dong HJ, Zhang X, Chen CH, Lin YW, Tsai TJ, Lee RZ, Liu LF, Su TL. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. Bioorg Med Chem 2005, 13(12):3993-4006. 10.1016/j.bmc.2005.03.057, 15911312.
10. Su TL, Lin YW, Chou TC, Zhang X, Bacherikov VA, Chen CH, Liu LF, Tsai TJ. Potent antitumor 9-anilinoacridines and acridines bearing an alkylating N-mustard residue on the acridine chromophore: synthesis and biological activity. J Med Chem 2006, 49(12):3710-3718. 10.1021/jm060197r, 16759114.
11. Su TL. Development of DNA topoisomerase II-mediated anticancer agents, 3-(9-acridinylamino)-5-hydroxymethylanilines (AHMAs) and related compounds. Curr Med Chem 2002, 9(18):1677-1688.
12. Lee CH, Chou TC, Su TL, Yu J, Shao LE, Yu AL. BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors. Cancer Lett 2009, 276(2):204-211. 10.1016/j.canlet.2008.11.006, 19108949.
13. Kapuriya N, Kapuriya K, Dong H, Zhang X, Chou TC, Chen YT, Lee TC, Lee WC, Tsai TH, Naliapara Y, et al. Novel DNA-directed alkylating agents: design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker. Bioorg Med Chem 2009, 17(3):1264-1275. 10.1016/j.bmc.2008.12.022, 19124250.
14. Kapuriya N, Kapuriya K, Zhang X, Chou TC, Kakadiya R, Wu YT, Tsai TH, Chen YT, Lee TC, Shah A, et al. Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. Bioorg Med Chem 2008, 16(10):5413-5423. 10.1016/j.bmc.2008.04.024, 18450456.
15. Kim JH, Shin JH, Kim IH. Susceptibility and radiosensitization of human glioblastoma cells to trichostatin A, a histone deacetylase inhibitor. Int J Radiat Oncol Biol Phys 2004, 59(4):1174-1180. 10.1016/j.ijrobp.2004.03.001, 15234053.
16. Camphausen K, Brady KJ, Burgan WE, Cerra MA, Russell JS, Bull EE, Tofilon PJ. Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther 2004, 3(4):409-416.
17. McCord AM, Jamal M, Williams ES, Camphausen K, Tofilon PJ. CD133+ glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009, 15(16):5145-5153. 10.1158/1078-0432.CCR-09-0263, 19671863.
18. Dote H, Cerna D, Burgan WE, Carter DJ, Cerra MA, Hollingshead MG, Camphausen K, Tofilon PJ. Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine. Clin Cancer Res 2005, 11(12):4571-4579. 10.1158/1078-0432.CCR-05-0050, 15958643.
19. Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, Camphausen K, Tofilon PJ. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone). Clin Cancer Res 2006, 12(9):2912-2918. 10.1158/1078-0432.CCR-05-2860, 16675588.
20. Russell JS, Burgan W, Oswald KA, Camphausen K, Tofilon PJ. Enhanced cell killing induced by the combination of radiation and the heat shock protein 90 inhibitor 17-allylamino-17- demethoxygeldanamycin: a multitarget approach to radiosensitization. Clin Cancer Res 2003, 9(10 Pt 1):3749-3755.
21. Geldof AA, Slotman BJ. Radiosensitizing effect of cisplatin in prostate cancer cell lines. Cancer Lett 1996, 101(2):233-239. 10.1016/0304-3835(96)04140-7, 8620475.
22. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys 2004, 59(4):928-942. 10.1016/j.ijrobp.2004.03.005, 15234026.
23. Sinclair WK, Morton RA. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966, 29(3):450-474. 10.2307/3572025, 5924188.
24. Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003, 81(3):123-129. 10.1139/o03-042, 12897845.
25. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert MR, Black PM, Loeffler JS. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 2006, 12(15):4738-4746. 10.1158/1078-0432.CCR-06-0596, 16899625.
26. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K. In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide. Clin Cancer Res 2008, 14(3):931-938. 10.1158/1078-0432.CCR-07-1856, 18245557.
27. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004, 11(4):448-457. 10.1038/sj.cdd.4401359, 14713959.
28. Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000, 83(5):588-593. 10.1054/bjoc.2000.1316, 2363506, 10944597.
29. Tomasz M, Palom Y. The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity. Pharmacol Ther 1997, 76(1-3):73-87. 10.1016/S0163-7258(97)00088-0, 9535170.
30. Panasci L, Xu ZY, Bello V, Aloyz R. The role of DNA repair in nitrogen mustard drug resistance. Anticancer Drugs 2002, 13(3):211-220. 10.1097/00001813-200203000-00002, 11984064.
31. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J, Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 2005, 7(2):195-201. 10.1038/ncb1212, 15665856.
32. Kakadiya R, Dong H, Lee PC, Kapuriya N, Zhang X, Chou TC, Lee TC, Kapuriya K, Shah A, Su TL. Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes. Bioorg Med Chem 2009, 17(15):5614-5626. 10.1016/j.bmc.2009.06.018, 19576785.
33. Kakadiya R, Dong H, Kumar A, Narsinh D, Zhang X, Chou TC, Lee TC, Shah A, Su TL. Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard-quinoline conjugates having a urea or hydrazinecarboxamide linker. Bioorg Med Chem 2010, 18(6):2285-2299. 10.1016/j.bmc.2010.01.061, 20181487.
34. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008, 18(1):134-147. 10.1038/cr.2007.111, 18157161.
35. Zou H, Zhao S, Zhang J, Lv G, Zhang X, Yu H, Wang H, Wang L. Enhanced radiation-induced cytotoxic effect by 2-ME in glioma cells is mediated by induction of cell cycle arrest and DNA damage via activation of ATM pathways. Brain Res 2007, 1185:231-238. 10.1016/j.brainres.2007.07.092, 17980860.
36. Jin C, Wu H, Liu J, Bai L, Guo G. The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J Clin Pharm Ther 2007, 32(1):41-47. 10.1111/j.1365-2710.2007.00796.x, 17286788.
37. Furuta Y, Hunter N, Barkley T, Hall E, Milas L. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res 1988, 48(11):3008-3013.
38. Samuel T, Weber HO, Funk JO. Linking DNA damage to cell cycle checkpoints. Cell Cycle 2002, 1(3):162-168. 10.4161/cc.1.3.118, 12429926.
39. Herzinger T, Funk JO, Hillmer K, Eick D, Wolf DA, Kind P. Ultraviolet B irradiation-induced G2 cell cycle arrest in human keratinocytes by inhibitory phosphorylation of the cdc2 cell cycle kinase. Oncogene 1995, 11(10):2151-2156.
40. Kastan MB, Lim DS. The many substrates and functions of ATM. Nat Rev Mol Cell Biol 2000, 1(3):179-186. 10.1038/35043058, 11252893.
41. Collis SJ, Swartz MJ, Nelson WG, DeWeese TL. Enhanced radiation and chemotherapy-mediated cell killing of human cancer cells by small inhibitory RNA silencing of DNA repair factors. Cancer Res 2003, 63(7):1550-1554.
42. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998, 273(10):5858-5868. 10.1074/jbc.273.10.5858, 9488723.
43. Sedelnikova OA, Rogakou EP, Panyutin IG, Bonner WM. Quantitative detection of (125)IdU-induced DNA double-strand breaks with gamma-H2AX antibody. Radiat Res 2002, 158(4):486-492. 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2, 12236816.
44. Olive PL, Banath JP. Phosphorylation of histone H2AX as a measure of radiosensitivity. Int J Radiat Oncol Biol Phys 2004, 58(2):331-335. 10.1016/j.ijrobp.2003.09.028, 14751500.
45. Nazarov IB, Smirnova AN, Krutilina RI, Svetlova MP, Solovjeva LV, Nikiforov AA, Oei SL, Zalenskaya IA, Yau PM, Bradbury EM, et al. Dephosphorylation of histone gamma-H2AX during repair of DNA double-strand breaks in mammalian cells and its inhibition by calyculin A. Radiat Res 2003, 160(3):309-317. 10.1667/RR3043, 12926989.
46. Banath JP, Macphail SH, Olive PL. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res 2004, 64(19):7144-7149. 10.1158/0008-5472.CAN-04-1433, 15466212.
47. Bilsland E, Downs JA. Tails of histones in DNA double-strand break repair. Mutagenesis 2005, 20(3):153-163. 10.1093/mutage/gei031, 15843385.
48. Lobrich M, Jeggo PA. Harmonising the response to DSBs: a new string in the ATM bow. DNA Repair (Amst) 2005, 4(7):749-759. 10.1016/j.dnarep.2004.12.008, 15978533.
49. Mitchell JB, Choudhuri R, Fabre K, Sowers AL, Citrin D, Zabludoff SD, Cook JA. In vitro and in vivo radiation sensitization of human tumor cells by a novel checkpoint kinase inhibitor, AZD7762. Clin Cancer Res 2010, 16(7):2076-2084. 10.1158/1078-0432.CCR-09-3277, 20233881.
50. Lehmann BD, McCubrey JA, Terrian DM. Radiosensitization of Prostate Cancer by Priming the Wild-Type p53-Dependent Cellular Senescence Pathway. Cancer Biol Ther 2007, 6(8):1165-1170. 2889025, 18059157.
51. Fujiwara K, Iwado E, Mills GB, Sawaya R, Kondo S, Kondo Y. Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy. Int J Oncol 2007, 31(4):753-760.
52. Kim KW, Hwang M, Moretti L, Jaboin JJ, Cha YI, Lu B. Autophagy upregulation by inhibitors of caspase-3 and mTOR enhances radiotherapy in a mouse model of lung cancer. Autophagy 2008, 4(5):659-668.
53. Tsuboi Y, Kurimoto M, Nagai S, Hayakawa Y, Kamiyama H, Hayashi N, Kitajima I, Endo S. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. J Neurosurg 2009, 110(3):594-604. 10.3171/2008.8.JNS17648, 19046042.